agg-523
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00380900)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- AggrecanaseINHIBITOR
Aggrecanase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(Cc1ccc(F)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)c1ccc(-c2ccccc2)cc1- Mol. weight
- 476.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4859268 ↗
Also known as
- agg-523
- agg-523
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00454298 | Phase 1 | May 1, 2007 | Pfizer, Wyeth |
| NCT00427687 | Phase 1 | Feb 1, 2007 | Pfizer, Wyeth |
| NCT00434785 | Phase 1 | Feb 1, 2007 | Pfizer, Wyeth |
| NCT00369304 | Phase 1 | Jul 1, 2006 | Pfizer, Wyeth |
| NCT00380900 | Phase 1 | Jul 1, 2006 | Pfizer, Wyeth |
Showing 5 of 5 trials
Page 1 / 1